Characterization of a Protective Monoclonal AntibodyRecognizing Staphylococcus aureus MSCRAMM ProteinClumping FactorA
Autor: | Andrea Hall, Patel Pratisksha, Jeff T. Hutchins, Michael A. Johnson, Julia M. Ross, John Vernachio, Elena Gorovits, Paul Domanski, Peter J. Syribeys, Joseph M. Patti |
---|---|
Rok vydání: | 2003 |
Předmět: |
Coagulase
Staphylococcus aureus medicine.drug_class Immunology Virulence Biology medicine.disease_cause Monoclonal antibody Fibrinogen Microbiology Bacterial Adhesion Virulence factor Mice In vivo medicine Animals Humans Adhesins Bacterial Mice Inbred BALB C Hybridomas Antibodies Monoclonal Bacterial Infections Staphylococcal Infections Surface Plasmon Resonance Antibodies Bacterial Clumping factor A Infectious Diseases Immunization Parasitology MSCRAMM medicine.drug |
Zdroj: | Infection and Immunity. 71:6864-6870 |
ISSN: | 1098-5522 0019-9567 |
DOI: | 10.1128/iai.71.12.6864-6870.2003 |
Popis: | The Staphylococcus aureus MSCRAMM (microbial surface components recognizing adhesive matrix molecules) protein clumping factor A (ClfA) has been shown to be a critical virulence factor in several experimental models of infection. This report describes the generation, characterization, and in vivo evaluation of a murine monoclonal antibody (MAb) against ClfA. Flow cytometric analysis revealed that MAb 12-9 recognized ClfA protein expressed by all of the clinical S. aureus strains obtained from a variety of sources. In assays measuring whole-cell S. aureus binding to human fibrinogen, MAb 12-9 inhibited S . aureus binding by over 90% and displaced up to 35% of the previously adherent S. aureus bacteria. Furthermore, a single infusion of MAb 12-9 was protective against an intravenous challenge with a methicillin-resistant strain of S. aureus in a murine sepsis model ( P < 0.0001). These data suggest that anti-ClfA MAb 12-9 should be further investigated as a novel immunotherapy for the treatment and prevention of life-threatening S. aureus infections. |
Databáze: | OpenAIRE |
Externí odkaz: |